Drug Trial Radar · NCT06253546
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 28, 2024
Primary completion
Jun 12, 2025
Study completion Jun 12, 2025
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia. Secondary Objectives: * To evaluate the pharmacokinetics (PK) of single doses of TV-44749 administered sc. * To evaluate the pharmacokinetics of oral olanzapine tablets following multiple dose administration. * To monitor the safety and tolerability of multiple doses of oral olanzapine tablets given in the study.
Conditions
- Schizophrenia
Interventions
TV-44749 318mgDrug
Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection
Oral Olanzapine 10mg/dayDrug
Pharmaceutical form: tablet Route of administration: oral
TV-44749 425mgDrug
Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection
Oral Olanzapine 15mg/dayDrug
Pharmaceutical form: tablet Route of administration: oral
TV-44749 531mgDrug
Pharmaceutical form: extended-release injectable suspension Route of administration: subcutaneous injection
Oral Olanzapine 20mg/dayDrug
Pharmaceutical form: tablet Route of administration: oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Period 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 Up to Day 43
- Period 2: Number of Participants With Treatment Emergent SAEsTime frame: Day 1 Up to Day 43
- Period 2: Number of Participants With Injection Site AEsTime frame: Day 1 Up to Day 43
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Teva Investigational Site 88049
Beijing, China
Teva Investigational Site 88048
Beijing, China
Teva Investigational Site 88047
Guangzhou, China
Teva Investigational Site 88046
Shanghai, China
Teva Investigational Site 88050
Wuhan, China
Teva Investigational Site 88056
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.